Blog
RSS FeedPosted by Michael Wonder on 19 Aug 2020
Mylan brings critical access to the multiple sclerosis community by launching a more affordable treatment option through a first generic to Tecfidera
19 August 2020 - Mylan today announced the launch of the first FDA approved therapeutically equivalent, substitutable generic of Biogen's ...
Posted by Michael Wonder on 13 Aug 2020
Drug prices fall in Switzerland but generics remain expensive
13 August 2020 - Switzerland is narrowing the gap with other European countries when it comes to the cost of medicines. ...
Posted by Michael Wonder on 03 Aug 2020
Medicare Part D plans rarely cover brand name drugs when generics are available
3 August 2020 - Study examines Medicare Part D coverage to quantify how often brand-name drugs are designated preferred over generics. ...
Posted by Michael Wonder on 22 Jul 2020
Epilepsy medicine linked to deaths not same as previous funded drug — advocacy group
22 July 2020 - Testing commissioned by Patient Voice Aotearoa, a patient advocacy group, shows the three medicines given in New ...
Posted by Michael Wonder on 20 Jul 2020
Grieving families lobby Parliament to reverse epilepsy drug brand switch
21 July 2020 - It has been more than nine months since PHARMAC switched to funding epilepsy drug Logem – a ...
Posted by Michael Wonder on 14 Jul 2020
Teva announces availability of ProAir Digihaler (salbutamol sulphate 117 mcg) inhalation powder for patients with asthma and COPD
13 July 2020 - First and only digital rescue inhaler with built-in sensors now available by prescription to patients in the ...
Posted by Michael Wonder on 14 Jul 2020
Alnylam announces that the United Kingdom’s MHRA grants early access to lumasiran
13 July 2020 - Positive scientific opinion under Early Access to Medicines Scheme will make lumasiran treatment available for UK primary ...
Posted by Michael Wonder on 13 Jul 2020
Doctors and patients anxious after pharma giant Apotex quits New Zealand
13 July 2020 - A patient advocate group says a pharmaceutical giant's decision to pull out of the New Zealand ...
Posted by Michael Wonder on 07 Jul 2020
Unsustainable low prices causing generic drug market failure leading to supply chain disruptions and shortages
6 July 2020 - Ongoing disruptions in the globalised pharma supply chains causing drug shortages in the United States are ...
Posted by Michael Wonder on 05 Jul 2020
A million Kiwis to be impacted by major pharmaceutical company leaving New Zealand
3 July 2020 - More than a million Kiwis may need to change to different medications before the end of ...
Posted by Michael Wonder on 29 Jun 2020
‘Government should lower prices of generic drugs’
29 June 2020 - “Our policy should aim at reaching the OECD average of general drug use, additionally cut generic ...
Posted by Michael Wonder on 16 Jun 2020
Supreme Court will not hear generic drug price fixing discovery dispute
16 June 2020 - The U.S. Supreme Court on Monday declined to hear generic drug makers’ challenge to a court ...
Posted by Michael Wonder on 10 Jun 2020
Coalition of attorneys general file third lawsuit against generic drug ‘price-fixing’
10 June 2020 - New York Attorney General Letitia James announced on 10 June, that she and a coalition of 51 ...
Posted by Michael Wonder on 02 Jun 2020
Estimating the cost of delayed generic drug entry to Medicaid
1 June 2020 - Delays in market entry of generic drugs are common. ...
Posted by Michael Wonder on 25 May 2020
First generic version of Gilead’s remdesivir will be sold by a Bangladesh drug maker
22 May 2020 - A drug maker in Bangladesh has become the first company to sell a generic version of ...